The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...

FDA grants full approval to Moderna's COVID-19 vaccine for children aged 6 months to 11 years with medical vulnerabilities, ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune ...

The Food and Drug Administration Thursday granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...

US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...

SILVER SPRING, MD — The FDA gives full approval for Moderna’s COVID-19 vaccine in children aged 6 months through 11 years who ...

The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months ...

Photo: Adobe Stock Despite the CDC’s move to kick the COVID-19 vaccine off recommended immunization schedules for children ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.